CDK4 and neoplasm: Second, as indications for certain adjuvant therapies rely upon high-risk anatomic features including nodal positivity, patients with ILC may be deemed ineligible for treatment such as CDK4/6 inhibitors, as they are less likely to have other tumor features like high grade or high Ki67 [50–52].